

LIMAY
BIOSCIENCES

Bridging the diagnostic gap



Easy to use & affordable diagnostics for underserved areas.

Simple and accessible solutions to **bridge the gap**,
enabling life-saving decisions on infectious diseases and
antibiotic resistance **where they are needed most.**

Lack of access to diagnostics hurt those who need it most



1.1 million

Avoidable deaths per year with access to basic diagnostics that lead to appropriate treatment.



81 %

Of the population in low-income countries don't have access to proper diagnosis.



\$750 billion

Wasted on unnecessary services and treatments due to inaccurate diagnoses per year.

1. Fleming, K. A., Horton, S., Wilson, M. L., Atun, R., DeStigter, K., Flanigan, J., Sayed, S., Adam, P., Aguilar, B., Andronikou, S. (2021). The Lancet Commission on diagnostics: transforming access to diagnostics. The Lancet, 398(10315), 1997-2050. Recuperado de: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(21\)00673-5/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00673-5/fulltext)
2. Smith M, Saunders R, Stuckhardt L, McGinnis JM (2013). Committee on the Learning Health Care System in America; Institute of Medicine. Best Care at Lower Cost: The Path to Continuously Learning Health Care in America. Washington (DC): National Academies Press (US); 2013 May 10. PMID: 24901184. Recuperado de: <https://pubmed.ncbi.nlm.nih.gov/24901184/>

Breaking barriers to molecular diagnostic access

CENTRALIZED

Transportation of samples to centralized laboratories.



PORTABLE

PCR-like sensitivity diagnosis in the place and time they is needed.

DELAYS

Wait for days or weeks to get the results.



INSTANTANEOUS

Results in minutes.

COMPLEX

Tests have to be performed by specialists.



EASY TO USE

Tests can be performed with minimal training.

HIGH COSTS

Equipment:
More than USD 35.000.-



LOW COSTS

Equipment:
Less than USD 1.000.-

The development of our end-to-end solutions embraces:



**Molecular biology
(Reagents)**



**Microengineering
(Devices)**



Boosted by AI

Our SMART[®] technology

- **Reliable results without complex equipment**

Functional at room temperature, for diagnostics whenever and wherever.

- **PCR-Like Sensitivity**

Matches lab-based testing standards in a portable format

- **Affordable Testing**

High-quality molecular diagnostics at a fraction of the cost and time of traditional labs.



Transforming Diagnostics with Continuous Innovation

Total alignment with WHO's Criteria* for point-of-care systems

	PCR / QPCR	GADx (lateral flow)	Cepheid	Visby Medical	SMART®
Affordable	> 10.000 USD	10 USD	> 3.600 USD	75 USD	15 USD
Sensitive	✓		✓	✓	✓
Specific	✓		✓	✓	✓
User Friendly		✓		✓	✓
Rapid	3 Hours	20 Mins	+ 1.5 Hours	40 Mins	< 60 Mins
Deliverable		✓		✓	✓

*[WHO's Criteria for POCT's](#)

High-impact opportunity driven by the large, growing, and underserved diagnostics market

TAM

USD 49 B

Global molecular diagnostic market

SAM

USD 1.9 B

High-Burden LATAM Facilities Ready for POC Molecular Testing

SOM

USD 4 M


*2 M Limay Revenue

2-year market penetration in priority LATAM regions

** 400 basic care units ~250,000 tests



Our Razor-Blade Business Model



Our strong pipeline with imminent commercial launches



Commercial partners financed development and catalyzed our Go-to-Market



Our First Tests 2021

Our first products were developed with support from Bioceres and Tecnoplant, who funded our early work on molecular tests for GMO detection



Dengue Fever Test 2023

We partnered with Infinity Pharma for the **development and commercialization** of our Dengue Fever tests.

This test is already approved by ANMAT.



Respiratory Panel 2024

We partnered with Wiener Labs, a leading company in in-vitro diagnostics in LATAM, for the **development, production and commercialization** of our Respiratory Panel.

Our founding team: a blend of science and entrepreneurship

LIMAY
BIOSCIENCES

Dolores G. Morón
CSO

- Co-Founded the first Neurogenetics clinic in Argentina.
- Ex Neurologist at the Acute Neuro- rehabilitation Unit in Switzerland's *Centre Hospitalier Universitaire Vaudois*

Marcelo Kauffman
Co-CEO & CTO

- Co-Founded the first Neurogenetics clinic in Argentina.
- Honorary visiting scholar at the University of Cincinnati.
- Led the Precision Medicine Program at Austral University in Buenos Aires.

Federico Scagliotti
Co-CEO & CBDO

- +7 companies funded.
- Extensive track record building strategic partnerships across America and Europe.



Ariel Notcovich
-ADVISOR-
+25 years exp.

**Diagnostics, Health
& Biotech**

Based in San Francisco, USA

BIO-RAD

BlueLight
Therapeutics



Marcelo Criscuolo
-ADVISOR-
+35 years exp.
Health & Biotech



Platinum Konex
Award:
Biotechnology



Join the revolution & let's change the world!

www.limay.bio

Federico Scagliotti
Founder & Co-CEO
fs@limay.bio